NCT03685500View on ClinicalTrials.gov

A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c)

PHASE4CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

December 4, 2018

Primary Completion Date

June 25, 2020

Study Completion Date

June 25, 2020

Conditions
HIV Infections
Interventions
DRUG

Symtuza® (TAF/FTC/DRV/c)

Treatment with TAF/FTC/DRV/c during 8 weeks since randomized

DRUG

ABC/3TC/DTG + Symtuza® (TAF/FTC/DRV/c)

Patients continuing on treatment with DTG/3TC/ABC after the randomization for 4 weeks, and then switch to TAF/FTC/DRV/c for 8 weeks

Trial Locations (6)

28041

Hospital Univ. 12 de Octubre, Madrid

Unknown

Hospital Puerta de Hierro, Majadahonda

H. Univ. Príncipe de Asturias, Madrid

Hospital Fundación Jimenez Diaz, Madrid

Hospital Infanta Leonor, Madrid

Hospital Universitario La Paz, Madrid

All Listed Sponsors
collaborator

Janssen-Cilag, S.A.

INDUSTRY

lead

Fundacion SEIMC-GESIDA

OTHER

NCT03685500 - A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c) | Biotech Hunter | Biotech Hunter